Cognitive impairment is an increasingly recognized major cause of chronic disability and is commonly found in patients with chronic kidney disease (CKD). Knowledge of the relationship between kidney dysfunction and impaired cognition may improve our understanding of other forms of cognitive dysfunction. Patients with CKD are at an increased risk (compared with the general population) of both dementia and its prodrome, mild cognitive impairment (MCI), which are characterized by deficits in executive functions, memory and attention. Brain imaging in patients with CKD has revealed damage to white matter in the prefrontal cortex and, in animal models, in the subcortical monoaminergic and cholinergic systems, accompanied by widespread macrovascular and microvascular damage. Unfortunately, current interventions that target cardiovascular risk factors (such as anti-hypertensive drugs, anti-platelet agents and statins) seem to have little or no effect on CKD-associated MCI, suggesting that the accumulation of uraemic neurotoxins may be more important than disturbed haemodynamic factors or lipid metabolism in MCI pathogenesis. Experimental models show that the brain monoaminergic system is susceptible to uraemic neurotoxins and that this system is responsible for the altered sleep pattern commonly observed in patients with CKD. Neural progenitor cells and the glymphatic system, which are important in Alzheimer disease pathogenesis, may also be involved in CKD-associated MCI. More detailed study of CKD-associated MCI is needed to fully understand its clinical relevance, underlying pathophysiology, possible means of early diagnosis and prevention, and whether there may be novel approaches and potential therapies with wider application to this and other forms of cognitive decline.
Cognitive impairment is more common in patients with chronic kidney disease (CKD) and those with reduced renal function than in the general population.
Cognitive dysfunction in patients with CKD ranges in severity from mild cognitive impairment (MCI) to dementia and involves deficiency in multiple cognitive domains, such as memory, attention, language and visuospatial skills, and executive functions.
Brain dysfunction in patients with CKD likely results from uraemic neurotoxins interacting with neural progenitor cells, the brain vasculature, the glymphatic system and monoaminergic neurons.
Targeting these mechanisms could potentially reduce the burden of dementia in CKD and might aid in the discovery of improved treatments for other forms of cognitive impairment.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 5th edn (American Psychiatric Association, 2013).
Marcos, G. et al. Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen’s criteria. Acta Psychiatr. Scand. 133, 378–385 (2016).
Viggiano, D. et al. Mild cognitive impairment and kidney disease: clinical aspects. Nephrol. Dial. Transplant. 35, 10–17 (2019).
Jellinger, K. A. Should the word ‘dementia’ be forgotten? J. Cell. Mol. Med. 14, 2415–2416 (2010).
Lipnicki, D. M. et al. Risk factors for mild cognitive impairment, dementia and mortality: the Sydney Memory and Ageing Study. J. Am. Med. Dir. Assoc. 18, 388–395 (2017).
Brodski, J., Rossell, S. L., Castle, D. J. & Tan, E. J. A systematic review of cognitive impairments associated with kidney failure in adults before natural age-related changes. J. Int. Neuropsychol. Soc. 25, 101–114 (2019).
Ekblad, L. L. et al. Albuminuria and microalbuminuria as predictors of cognitive performance in a general population: an 11-year follow-up study. J. Alzheimers Dis. 65, 1053–1054 (2018). A study confirming the role of proteinuria, a marker of endothelial dysfunction, in cognitive impairment; this study is notable for the long follow-up.
Martens, R. J. H. et al. Estimated GFR, albuminuria, and cognitive performance: the Maastricht Study. Am. J. Kidney Dis. 69, 179–191 (2017). A large cohort study confirming the role of proteinuria in MCI.
Weiner, D. E. et al. Cognitive function and kidney disease: baseline data from the systolic blood pressure intervention trial (SPRINT). Am. J. Kidney Dis. 70, 357–367 (2017).
Berger, I. et al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med. 14, 1–10 (2016).
Mendley, S. R. et al. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 87, 800–806 (2015). A pivotal study demonstrating that even children are at risk of developing cognitive impairment when CKD is present.
Sacre, J. W. et al. Associations of chronic kidney disease markers with cognitive function: a 12-year follow-up study. J. Alzheimers Dis. 70, 1–12 (2018).
O’Lone, E. et al. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis. Am. J. Kidney Dis. 67, 925–935 (2016).
Harhay, M. N. et al. Cognitive impairment in non–dialysis-dependent CKD and the transition to dialysis: findings from the chronic renal insufficiency cohort (CRIC) study. Am. J. Kidney Dis. 72, 499–508 (2018).
Chu, N. M. et al. Frailty and changes in cognitive function after kidney transplantation. J. Am. Soc. Nephrol. 30, 336–345 (2019).
Drew, D. A., Weiner, D. E. & Sarnak, M. J. Cognitive impairment in CKD: pathophysiology, management, and prevention. Am. J. Kidney Dis. 74, 782–790 (2019).
Zammit, A. R., Katz, M. J., Bitzer, M. & Lipton, R. B. Cognitive impairment and dementia in older adults with chronic kidney disease: a review. Alzheimer Dis. Assoc. Disord. 30, 357–366 (2016).
Chillon, J.-M., Massy, Z. A. & Stengel, B. Neurological complications in chronic kidney disease patients. Nephrol. Dial. Transpl. 31, 1606–1614 (2016).
Kurella Tamura, M. et al. Vascular risk factors and cognitive impairment in chronic kidney disease: the chronic renal insufficiency cohort (CRIC) study. Clin. J. Am. Soc. Nephrol. 6, 248–256 (2011). A landmark study of cognitive impairment in CKD.
Kelly, D. & Rothwell, P. M. Disentangling the multiple links between renal dysfunction and cerebrovascular disease. J. Neurol. Neurosurg. Psychiatry 91, 88–97 (2019).
Lu, R., Kiernan, M. C., Murray, A., Rosner, M. H. & Ronco, C. Kidney–brain crosstalk in the acute and chronic setting. Nat. Rev. Nephrol. 11, 707–719 (2015).
Lizio, R. et al. Different abnormalities of cortical neural synchronization mechanisms in patients with mild cognitive impairment due to Alzheimer’s and chronic kidney diseases: an EEG study. J. Alzheimers Dis. 65, 897–915 (2018). A study directly comparing cognitive impairment in Alzheimer disease with that in CKD.
Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers. Dement. 7, 270–279 (2011).
Burns, C. M. et al. Prevalence and risk of severe cognitive impairment in advanced chronic kidney disease. J. Gerontol. A Biol. Sci. Med. Sci. 73, 393–399 (2018).
Otobe, Y. et al. Mild cognitive impairment in older adults with pre-dialysis patients with chronic kidney disease: prevalence and association with physical function. Nephrology 24, 50–55 (2019).
Hobson, P., Lewis, A., Nair, H., Wong, S. & Kumwenda, M. How common are neurocognitive disorders in patients with chronic kidney disease and diabetes? Results from a cross-sectional study in a community cohort of patients in North Wales, UK. BMJ Open 8, e023520 (2018).
Kalirao, P. et al. Cognitive impairment in peritoneal dialysis patients. Am. J. Kidney Dis. 57, 612–620 (2011).
Manly, J. J. et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann. Neurol. 63, 494–506 (2008).
Ponjoan, A. et al. Epidemiology of dementia: prevalence and incidence estimates using validated electronic health records from primary care. Clin. Epidemiol. 11, 217–228 (2019).
McAdams-DeMarco, M. A. et al. Dementia and Alzheimer’s disease among older kidney transplant recipients. J. Am. Soc. Nephrol. 28, 1575–1583 (2017). An important study of cognitive impairment in kidney transplant recipients.
van der Flier, W. M. & Scheltens, P. Epidemiology and risk factors of dementia. J. Neurol. Neurosurg. Psychiatry 76, v2–v7 (2005).
Kurella Tamura, M. & Yaffe, K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int. 79, 14–22 (2011).
Kuo, Y.-T. et al. Risk of dementia in patients with end-stage renal disease under maintenance dialysis — a nationwide population-based study with consideration of competing risk of mortality. Alzheimers Res. Ther. 11, 31 (2019).
McAdams-Demarco, M. A. et al. Frailty and cognitive function in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 10, 2181–2189 (2015). A landmark study of cognitive dysfunction in patients on haemodialysis.
Fukunishi, I. et al. Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 91, 344–347 (2002).
US Renal Data System. USRDS 2005 annual data report: atlas of end-stage renal disease in the United States 140–143 (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005).
McAdams-DeMarco, M. A. et al. Dementia, Alzheimer’s disease, and mortality after hemodialysis initiation. Clin. J. Am. Soc. Nephrol. 13, 1339–1347 (2018).
Joosten, H. et al. Association of cognitive function with albuminuria and eGFR in the general population. Clin. J. Am. Soc. Nephrol. 6, 1400–1409 (2011).
Madan, P., Kalra, O. P., Agarwal, S. & Tandon, O. P. Cognitive impairment in chronic kidney disease. Nephrol. Dial. Transpl. 22, 440–444 (2007).
Singh, N. P. et al. Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial. Int. 10, 267–273 (2006).
Sharma, A. et al. Impact of cognitive function change on mortality in renal transplant and end-stage renal disease patients. Am. J. Nephrol. 44, 462–472 (2016).
Qiu, Y. et al. Structural and functional brain alterations in end stage renal disease patients on routine hemodialysis: a voxel-based morphometry and resting state functional connectivity study. PLoS One 9, e98346 (2014).
Song, S. H., Kim, I. J., Kim, S.-J., Kwak, I. S. & Kim, Y.-K. Cerebral glucose metabolism abnormalities in patients with major depressive symptoms in pre-dialytic chronic kidney disease: statistical parametric mapping analysis of F-18-FDG PET, a preliminary study. Psychiatry Clin. Neurosci. 62, 554–561 (2008).
Tian, X. et al. The comparison of cognitive function and risk of dementia in CKD patients under peritoneal dialysis and hemodialysis: a PRISMA-compliant systematic review and meta-analysis. Medicine 98, e14390 (2019).
Boccardi, M. et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol. Aging 24, 95–103 (2003).
Blamire, A. M. MR approaches in neurodegenerative disorders. Prog. Nucl. Magn. Reson. Spectrosc. 108, 1–16 (2018).
Palkovits, M. et al. Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease — modulatory effects of losartan and moxonidine. PLoS One 8, e66543 (2013).
Mazumder, M. K., Paul, R., Bhattacharya, P. & Borah, A. Neurological sequel of chronic kidney disease: from diminished Acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Sci. Rep. 9, 3097 (2019).
Deng, G., Vaziri, N. D., Jabbari, B., Ni, Z. & Yan, X. X. Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J. Am. Soc. Nephrol. 12, 1892–1899 (2001).
Jones, D. J. W. et al. The nature of impairments of memory in patients with end-stage renal disease (ESRD). Physiol. Behav. 147, 324–333 (2015).
Kim, J. W., Ha, G. Y. & Jung, Y. W. Chronic renal failure induces cell death in rat hippocampal CA1 via upregulation of αCaMKII/NR2A synaptic complex and phosphorylated GluR1-containing AMPA receptor cascades. Kidney Res. Clin. Pract. 33, 132–138 (2014).
Viggiano, D. et al. Quantifying barcodes of dendritic spines using entropy-based metrics. Sci. Rep. 5, 14622 (2015).
Viggiano, D. et al. Information content of dendritic spines after motor learning. Behav. Brain Res. 336, 256–260 (2018).
Kurella, M., Yaffe, K., Shlipak, M. G., Wenger, N. K. & Chertow, G. M. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis. 45, 66–76 (2005).
Puy, L. et al. Cognitive impairments and dysexecutive behavioral disorders in chronic kidney disease. J. Neuropsychiatry Clin. Neurosci. 30, 310–317 (2018).
Yaffe, K. et al. Chronic kidney disease and cognitive function in older adults: findings from the Chronic Renal Insufficiency Cohort (CRIC) cognitive study. J. Am. Geriatr. Soc. 58, 338–345 (2010). A study linking lower kidney function with cognitive impairment in older patients with CKD.
Vemuri, P. et al. Association of kidney function biomarkers with brain MRI findings: the BRINK study. J. Alzheimers Dis. 55, 1069–1082 (2017). A landmark paper reporting the brain MRI findings in a large cohort, a substantial proportion of which were patients with CKD.
Hartung et al. Brain magnetic resonance imaging findings in children and young adults with CKD. Am. J. Kidney Dis. 72, 349–359 (2018).
Giorgio, A. et al. Relevance of brain lesion location for cognition in vascular mild cognitive impairment. NeuroImage Clin. 22, 101789 (2019).
Troen, A. M. et al. Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT). J. Ren. Nutr. 22, 268–276.e3 (2012).
Lee, S. C. et al. The association between kidney function and cognitive decline in community-dwelling, elderly Japanese people. J. Am. Med. Dir. Assoc. 16, 349.e1–349.e5 (2015).
Drew, D. A. et al. Cognitive decline and its risk factors in prevalent hemodialysis patients. Am. J. Kidney Dis. 69, 780–787 (2017).
Griva, K. et al. Neuropsychological performance after kidney transplantation: a comparison between transplant types and in relation to dialysis and normative data. Nephrol. Dial. Transplant. 19, 1866–1874 (2004).
Matsuda-Abedini, M. et al. Brain abnormalities in children and adolescents with chronic kidney disease. Pediatr. Res. 84, 387–392 (2018). An important study detailing the morphological changes that occur in the brain in children with CKD.
Johnson, K. A., Fox, N. C., Sperling, R. A. & Klunk, W. E. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006213 (2012).
Lenzenweger, M. F. Thinking clearly about the endophenotype-intermediate phenotype-biomarker distinctions in developmental psychopathology research. Dev. Psychopathol. 25, 1347–1357 (2013).
Maung, S. C., El Sara, A., Chapman, C., Cohen, D. & Cukor, D. Sleep disorders and chronic kidney disease. World J. Nephrol. 5, 224–232 (2016).
Kennedy, C., Ryan, S. A., Kane, T., Costello, R. W. & Conlon, P. J. The impact of change of renal replacement therapy modality on sleep quality in patients with end-stage renal disease: a systematic review and meta-analysis. J. Nephrol. 31, 61–70 (2018).
Elias, R. M., Chan, C. T. & Bradley, T. D. Altered sleep structure in patients with end-stage renal disease. Sleep Med. 20, 67–71 (2016).
Zoccali, C., Mallamaci, F. & Tripepi, G. Sleep apnea in renal patients. J. Am. Soc. Nephrol. 12, 2854–2859 (2001).
Marrone, O. et al. Chronic kidney disease in European patients with obstructive sleep apnea: the ESADA cohort study. J. Sleep. Res. 25, 739–745 (2016).
Forni Ogna, V. et al. Prevalence and diagnostic approach to sleep apnea in hemodialysis patients: a population study. Biomed. Res. Int. 2015, 103686 (2015).
Huang, S.-T. et al. Risk, severity, and predictors of obstructive sleep apnea in hemodialysis and peritoneal dialysis patients. Int. J. Environ. Res. Public Health 15, E2377 (2018).
Tsampalieros, A. et al. Obstructive sleep apnea and hypertension in pediatric chronic kidney disease. Pediatr. Nephrol. 34, 2361–2370 (2019).
Nigam, G., Pathak, C. & Riaz, M. A systematic review of central sleep apnea in adult patients with chronic kidney disease. Sleep Breath. 20, 957–964 (2016).
Tada, T. et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol. Dial. Transpl. 22, 1190–1197 (2007).
Zoccali, C., Mallamaci, F. & Tripepi, G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J. Am. Soc. Nephrol. 13, 729–733 (2002).
Zoccali, C., Mallamaci, F., Tripepi, G. & Benedetto, F. A. Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. Nephrol. Dial. Transpl. 16, 70–77 (2001).
Wennberg, A. M. V., Wu, M. N., Rosenberg, P. B. & Spira, A. P. Sleep disturbance, cognitive decline, and dementia: a review. Semin. Neurol. 37, 395–406 (2017).
Matsunaga, Y. et al. Effects of zolpidem/triazolam on cognitive performance 12 hours after acute administration. Sleep Med. 52, 213–218 (2018).
Suzuki, H. et al. Associations of regional brain structural differences with aging, modifiable risk factors for dementia, and cognitive performance. JAMA Netw. Open 2, e1917257 (2019).
Viggiano, D. The hyperactive syndrome: metanalysis of genetic alterations, pharmacological treatments and brain lesions which increase locomotor activity. Behav. Brain Res. 194, 1–14 (2008).
Aguilera, A., Sánchez-Tomero, J. A. & Selgas, R. Brain activation in uremic anorexia. J. Ren. Nutr. 17, 57–61 (2007).
Tran, J., Ayers, E., Verghese, J. & Abramowitz, M. Gait abnormalities and the risk of falls in CKD. Clin. J. Am. Soc. Nephrol. 14, 983–993 (2019).
Arnold, R., Issar, T., Krishnan, A. V. & Pussell, B. A. Neurological complications in chronic kidney disease. JRSM Cardiovasc. Dis. 5, 2048004016677687 (2016).
Hamed, S. A. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Rev. Clin. Pharmacol. 12, 61–90 (2019).
Owolabi, L. F. et al. Related factors and predictors of cognitive dysfunction in chronic kidney disease on maintenance hemodialysis in Nigeria. J. Neurosci. Rural. Pract. 7, S62–S67 (2016).
Hailpern, S. M., Melamed, M. L., Cohen, H. W. & Hostetter, T. H. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 18, 2205–2213 (2007).
Kumar, R. B. & Bhat, J. S. Voice in chronic renal failure. J. Voice 24, 690–693 (2010).
Marquis, S. et al. Independent predictors of cognitive decline in healthy elderly persons. Arch. Neurol. 59, 601–606 (2002).
Szczepańska-Gieracha, J., Cieślik, B., Chamela-Bilińska, D. & Kuczyński, M. Postural stability of elderly people with cognitive impairments. Am. J. Alzheimers Dis. Other Demen. 31, 241–246 (2016).
Tosto, G., Monsell, S. E., Hawes, S. E. & Mayeux, R. Pattern of extrapyramidal signs in Alzheimer’s disease. J. Neurol. 262, 2548–2556 (2015).
Hildebrandt, F. Genetic kidney diseases. Lancet 375, 1287–1295 (2010).
Landini, S. et al. Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 15, 89–100 (2020).
Verbitsky, M. et al. Genomic disorders and neurocognitive impairment in pediatric CKD. J. Am. Soc. Nephrol. 28, 2303–2309 (2017).
Caterino, M. et al. Urine proteomics revealed a significant correlation between urine-fibronectin abundance and estimated-GFR decline in patients with Bardet-Biedl Syndrome. Kidney Blood Press. Res. 43, 389–405 (2018).
Körver, S. et al. Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease. Sci. Rep. 9, 188 (2019).
Sigurdardottir, S., Myers, S. M., Woodworth, J. M. & Raymond, G. V. Mental retardation and seizure disorder in Schimke immunoosseous dysplasia. Am. J. Med. Genet. 90, 294–298 (2000).
Brancati, F., Dallapiccola, B. & Valente, E. M. Joubert Syndrome and related disorders. Orphanet J. Rare Dis. 5, 20 (2010).
Liu, A. J. et al. Association of cognitive and behavioral features between adults with tuberous sclerosis and frontotemporal dementia. JAMA Neurol. 77, 358–366 (2019).
Bökenkamp, A. & Ludwig, M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr. Nephrol. 31, 2201–2212 (2016).
Groopman, E. E. et al. Diagnostic utility of exome sequencing for kidney disease. N. Engl. J. Med. 380, 142–151 (2019).
Mengel-From, J. et al. Genetic variants in KLOTHO associate with cognitive function in the oldest old group. J. Gerontol. A Biol. Sci. Med. Sci. 71, 1151–1159 (2016).
Shardell, M. et al. Plasma Klotho and cognitive decline in older adults: findings from the InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 71, 677–682 (2016).
Wuttke, M. et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat. Genet. 51, 957–972 (2019). A keystone large-scale meta-analysis study identifying genetic loci associated with CKD.
De Sanctis, C., Bellenchi, G. C. & Viggiano, D. A meta-analytic approach to genes that are associated with impaired and elevated spatial memory performance. Psychiatry Res. 261, 508–516 (2018).
Moreno-Grau, S. et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks: The GR@ACE project. Alzheimers Dement. 15, 1333–1347 (2019).
Hunter, D. J. & Drazen, J. M. Has the genome granted our wish yet? N. Engl. J. Med. 380, 2391–2393 (2019).
Rodríguez-Rodríguez, E. et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer’s disease. J. Neural Transm. 120, 807–812 (2013).
Noguchi, Y., Nagasawa, H., Tachi, T., Tsuchiya, T. & Teramachi, H. Signal detection of oral drug-induced dementia in chronic kidney disease patients using association rule mining and Bayesian confidence propagation neural network. Pharmazie 74, 570–574 (2019).
Jessen, N. A., Munk, A. S. F., Lundgaard, I. & Nedergaard, M. The glymphatic system: a beginner’s guide. Neurochem. Res. 40, 2583–2599 (2015). A useful introduction to the glymphatic system.
Shah, S. V., Shukla, A. M., Bose, C., Basnakian, A. G. & Rajapurkar, M. Recent advances in understanding the pathogenesis of atherosclerosis in CKD patients. J. Ren. Nutr. 25, 205–208 (2015).
Ali, S., Dave, N., Virani, S. S. & Navaneethan, S. D. Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr. Atheroscler. Rep. 21, 32 (2019).
Bosch, A. et al. Retinal capillary and arteriolar changes in patients with chronic kidney disease. Microvasc. Res. 118, 121–127 (2018).
Gennip, A. C. E. van et al. Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. PLoS One 14, e0222547 (2019).
Lau, W. L. et al. Chronic kidney disease increases cerebral microbleeds in mouse and man. Transl. Stroke Res. 11, 122–134 (2020).
Nortley, R. et al. Amyloid beta oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes. Science 365, eaav9518 (2019).
Katherine, R. et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw. Open 2, e1918169 (2019).
Walker, K. et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA 322, 535–545 (2019).
Jiang, X. L. et al. Cerebral blood flow changes in hemodialysis and peritoneal dialysis patients: an arterial-spin labeling MR imaging. Metab. Brain Dis. 31, 929–936 (2016).
Liu, H.-S. et al. Regional cerebral blood flow in children and young adults with chronic kidney disease. Radiology 288, 849–858 (2018). A study reporting important functional MRI data in patients with CKD.
Cheng, B.-C. et al. Decreased cerebral blood flow and improved cognitive function in patients with end-stage renal disease after peritoneal dialysis: an arterial spin-labelling study. Eur. Radiol. 29, 1415–1424 (2019).
Moura, A. et al. Type of vascular access and location in online hemodiafiltration and its association with patient’s perception of health-related quality of life. J. Vasc. Access. 15, 175–182 (2014).
McGuire, S. et al. Hemodynamic instability during dialysis: the potential role of intradialytic exercise. Biomed. Res. Int. 2018, 8276912 (2018).
Polinder-Bos, H. A. et al. Hemodialysis induces an acute decline in cerebral blood flow in elderly patients. J. Am. Soc. Nephrol. 29, 1317–1325 (2018).
Farhoudi, M., Abedi Azar, S. & Abdi, R. Brain hemodynamics in patients with end-stage renal disease between hemodialysis sessions. Iran. J. Kidney Dis. 6, 110–113 (2012).
Tamura, M. K. et al. Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology 86, 1208–1216 (2016).
Markus, H. S. Genes, endothelial function and cerebral small vessel disease in man. Exp. Physiol. 93, 121–127 (2008).
Pabbidi, M. R. et al. Identification of a region of rat chromosome 1 that impairs the myogenic response and autoregulation of cerebral blood flow in fawn-hooded hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 304, H311–H317 (2013).
Fan, F. et al. Impaired myogenic response and autoregulation of cerebral blood flow is rescued in CYP4A1 transgenic Dahl salt-sensitive rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 308, R379–R390 (2015).
Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4, 147ra111 (2012).
Rasmussen, M. K., Mestre, H. & Nedergaard, M. The glymphatic pathway in neurological disorders. Lancet Neurol. 17, 1016–1024 (2018).
Plog, B. A. & Nedergaard, M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu. Rev. Pathol. 13, 379–394 (2018).
Palmer, K., Mitolo, M., Burgio, F., Meneghello, F. & Venneri, A. Sleep disturbance in mild cognitive impairment and association with cognitive functioning. A case-control study. Front. Aging Neurosci. 10, 360 (2018).
Menon, R. N. et al. Do quantified sleep architecture abnormalities underlie cognitive disturbances in amnestic mild cognitive impairment? J. Clin. Neurosci. 67, 85–92 (2019).
Ju, Y.-E. S., Zangrilli, M. A., Finn, M. B., Fagan, A. M. & Holtzman, D. M. Obstructive sleep apnea treatment, slow wave activity, and amyloid-β. Ann. Neurol. 85, 291–295 (2019).
Mawuenyega, K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330, 1774 (2010).
Viggiano, D. et al. Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound. Kidney Blood Press. Res. 43, 606–615 (2018).
Yirmiya, R. & Goshen, I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181–213 (2011).
Yang, G. et al. Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 110, 10306–10311 (2013).
Li, C. et al. Roles of neuropeptide Y in neurodegenerative and neuroimmune diseases. Front. Neurosci. 13, 869 (2019).
Baker, D. G. et al. Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology 38, 2378–2382 (2013).
Kastin, A. J. & Akerstrom, V. Nonsaturable entry of neuropeptide Y into brain. Am. J. Physiol. 276, E479–E482 (1999).
Zoccali, C. et al. Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study. J. Hypertens. 37, 1359–1365 (2019).
Barceló, A. et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am. J. Respir. Crit. Care Med. 171, 183–187 (2005).
Zoccali, C. et al. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease. J. Am. Soc. Nephrol. 14, 2611–2617 (2003).
Cannon, J. A. et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J. Card. Fail. 23, 464–475 (2017).
Bründl, E. et al. Excessive release of endogenous neuropeptide Y into cerebrospinal fluid after treatment of spontaneous subarachnoid haemorrhage and its possible impact on self-reported neuropsychological performance — results of a prospective clinical pilot study on good-grade patients. Neurol. Res. 40, 1001–1013 (2018).
Singh, P. et al. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. J. Clin. Invest. 127, 4527–4540 (2017).
Choi, B. et al. Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation. Front. Immunol. 10, 1701 (2019).
Zhou, J.-R. et al. Neuropeptide Y induces secretion of high-mobility group Box 1 protein in mouse macrophage via Pkc/Erk dependent pathway. J. Neuroimmunol. 260, 55–59 (2013).
Geloso, M. C. et al. Cellular targets for neuropeptide Y-mediated control of adult neurogenesis. Front. Cell. Neurosci. 9, 85 (2015).
Lourida, I. et al. Parathyroid hormone, cognitive function and dementia: a systematic review. PLoS One 10, e0127574 (2015).
Kellett, K. A., Williams, J., Vardy, E. R., Smith, A. D. & Hooper, N. M. Plasma alkaline phosphatase is elevated in Alzheimer’s disease and inversely correlates with cognitive function. Int. J. Mol. Epidemiol. Genet. 2, 114–121 (2011).
Hagström, E. et al. Plasma parathyroid hormone is associated with vascular dementia and cerebral hyperintensities in two community-based cohorts. J. Clin. Endocrinol. Metab. 99, 4181–4189 (2014).
Díaz-Hernández, M. et al. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J. Biol. Chem. 285, 32539–32548 (2010).
Vervloet, M. Renal and extrarenal effects of fibroblast growth factor 23. Nat. Rev. Nephrol. 15, 109–120 (2019).
McGrath, E. R. et al. Circulating fibroblast growth factor 23 levels and incident dementia: the Framingham Heart Study. PLoS One 14, e0213321 (2019).
Kuro-O, M. The Klotho proteins in health and disease. Nat. Rev. Nephrol. 15, 27–44 (2019).
Zou, D. et al. The role of klotho in chronic kidney disease. BMC Nephrol. 19, 285 (2018).
Kuriyama, N. et al. Association between α-Klotho and deep white matter lesions in the brain: a pilot case control study using brain MRI. J. Alzheimers Dis. 61, 145–155 (2018).
Erickson, C. M. et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 92, e1878–e1889 (2019).
Paroni, G. et al. Klotho at the edge of Alzheimer’s disease and senile depression. Mol. Neurobiol. 56, 190–1920 (2019).
Zhu, L. et al. Klotho controls the brain–immune system interface in the choroid plexus. Proc. Natl Acad. Sci. USA 115, E11388–E11396 (2018).
Li, D. et al. Enhanced expression of secreted α-Klotho in the hippocampus alters nesting behavior and memory formation in mice. Front. Cell. Neurosci. 13, 133 (2019).
Nagai, T. et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 17, 50–52 (2003).
Laszczyk, A. M. et al. FGF-23 deficiency impairs hippocampal-dependent cognitive function. eNeuro 6, ENEURO.0469-18.2019 (2019).
Kosakai, A. et al. Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure. Brain Res. 1382, 109–117 (2011).
Selamet, U. et al. Serum calcitriol concentrations and kidney function decline, heart failure, and mortality in elderly community-living adults: the health, aging, and body composition study. Am. J. Kidney Dis. 72, 419–428 (2018).
Cui, X., Gooch, H., Petty, A., McGrath, J. J. & Eyles, D. Vitamin D and the brain: Genomic and non-genomic actions. Mol. Cell. Endocrinol. 453, 131–143 (2017).
Mayne, P. E. & Burne, T. H. J. Vitamin D in synaptic plasticity, cognitive function, and neuropsychiatric illness. Trends Neurosci. 42, 293–306 (2019).
Goodwill, A. M. & Szoeke, C. A systematic review and meta-analysis of the effect of low vitamin D on cognition. J. Am. Geriatr. Soc. 65, 2161–2168 (2017).
Sorrells, S. F. et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature 555, 377–381 (2018).
Ma, D. K., Bonaguidi, M. A., Ming, G.-L. & Song, H. Adult neural stem cells in the mammalian central nervous system. Cell Res. 19, 672–682 (2009).
Martino, G. & Pluchino, S. The therapeutic potential of neural stem cells. Nat. Rev. Neurosci. 7, 395–406 (2006).
De Feo, D., Merlini, A., Laterza, C. & Martino, G. Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr. Opin. Neurol. 25, 322–333 (2012).
Meng, C., Zhang, J.-C., Shi, R.-L., Zhang, S.-H. & Yuan, S.-Y. Inhibition of interleukin-6 abolishes the promoting effects of pair housing on post-stroke neurogenesis. Neuroscience 307, 160–170 (2015).
Wang, J. et al. Activated regulatory T cell regulates neural stem cell proliferation in the subventricular zone of normal and ischemic mouse brain through interleukin 10. Front. Cell. Neurosci. 9, 361 (2015).
Widera, D., Mikenberg, I., Elvers, M., Kaltschmidt, C. & Kaltschmidt, B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappaB signaling. BMC Neurosci. 7, 64 (2006).
Kokaia, Z., Martino, G., Schwartz, M. & Lindvall, O. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat. Neurosci. 15, 1078–1087 (2012).
Liu, Q. et al. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat. Neurosci. 19, 243–252 (2016).
Mohammad, M. G. et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J. Clin. Invest. 124, 1228–1241 (2014).
Skardelly, M. et al. The influence of immunosuppressive drugs on neural stem/progenitor cell fate in vitro. Exp. Cell Res. 319, 3170–3181 (2013).
Rudenko, A. et al. Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. Neuron 79, 1109–1122 (2013).
Zhou, H., Wang, B., Sun, H., Xu, X. & Wang, Y. Epigenetic regulations in neural stem cells and neurological diseases. Stem Cell Int. 2018, 6087143 (2018).
Posner, J. B., Plum, F., Saper, C. B. & Schiff, N. Plum and Posner’s Diagnosis of Stupor and Coma (Oxford Univ. Press, 2007).
Kelly, D. M. The role of dialysis in the pathogenesis and treatment of dementia. Nephrol. Dial. Transpl. 34, 1080–1083 (2019).
Giang, L. M. et al. Cognitive function and dialysis adequacy: no clear relationship. Am. J. Nephrol. 33, 33–38 (2011).
Lin, Y.-T. et al. Comparison of dementia risk between end stage renal disease patients with hemodialysis and peritoneal dialysis — a population based study. Sci. Rep. 5, 8224 (2015).
Joshee, P., Wood, A. G., Wood, E. R. & Grunfeld, E. A. Meta-analysis of cognitive functioning in patients following kidney transplantation. Nephrol. Dial. Transpl. 33, 1268–1277 (2018).
Gupta, A. et al. Cognitive function and white matter changes associated with renal transplantation. Am. J. Nephrol. 43, 50–57 (2016).
SPRINT MIND Investigators for the SPRINT Research Group. et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA 322, 524–534 (2019). A large study detailing the effects of intensive blood pressure control on the brain.
Brady, C. B. et al. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. Am. J. Kidney Dis. 54, 440–449 (2009).
Abu Ahmad, N. et al. L-Carnitine improves cognitive and renal functions in a rat model of chronic kidney disease. Physiol. Behav. 164, 182–188 (2016).
Farina, N., Isaac, M. G., Clark, A. R., Rusted, J. & Tabet, N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 11, CD002854 (2012).
Fujisaki, K. et al. Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol. Dial. Transpl. 29, 529–538 (2014).
Smith, P. J. & Blumenthal, J. A. Dietary factors and cognitive decline. J. Prev. Alzheimers Dis. 3, 53–64 (2016).
Dearborn-Tomazos, J. L. et al. Association of dietary patterns in midlife and cognitive function in later life in US adults without dementia. JAMA Netw. Open 2, e1916641 (2019).
Jáuregui-Lobera, I. Iron deficiency and cognitive functions. Neuropsychiatr. Dis. Treat. 10, 2087–2095 (2014).
Vinothkumar, G., Krishnakumar, S., Riya & Venkataraman, P. Correlation between abnormal GSK3β, β Amyloid, total Tau, p-Tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: impact of rHuEPO therapy. J. Clin. Neurosci. 69, 38–42 (2019).
Vinothkumar, G. et al. Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer’s disease: a pilot study. Biomed. Pharmacother. 104, 211–222 (2018).
Wallace, H. J., Wallace, I. R. & McCaffrey, P. Cognitive decline reversed by cinacalcet. QJM 108, 59–61 (2015).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
Liberale, L. et al. Post-ischaemic administration of the murine canakinumab-surrogate antibody improves outcome in experimental stroke. Eur. Heart J. 39, 3511–3517 (2018).
Sil, S., Ghosh, R., Sanyal, M., Guha, D. & Ghosh, T. A comparison of neurodegeneration linked with neuroinflammation in different brain areas of rats after intracerebroventricular colchicine injection. J. Immunotoxicol. 13, 181–190 (2016).
Rahman, M. R. et al. Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer’s disease: insights from a systems biomedicine perspective. Genomics 112, 1290–1299 (2020).
Huang, L. K., Chao, S. P. & Hu, C. J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 18 (2020).
Yiannopoulou, K. G., Anastasiou, A. I., Kyrozis, A. & Anastasiou, I. P. Donepezil treatment for Alzheimer’s disease in chronic dialysis patients. Case Rep. Nephrol. Dial. 9, 126–136 (2019).
Paez, A. AMBAR (Alzheimer’s management by albumin replacement) phase IIB/III results. J. Prev. Alzheimers Dis. https://www.ctad-alzheimer.com/files/files/CTAD%20OA.pdf (2018).
Cassano, T. et al. Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease. Exp. Neurol. 311, 88–105 (2019).
Watson, C. P. et al. The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro. Brain Res. 1648, 232–242 (2016).
Badran, M., Golbidi, S., Ayas, N. & Laher, I. Nitric oxide bioavailability in obstructive sleep apnea: interplay of asymmetric dimethylarginine and free radicals. Sleep Disord. 2015, 387801 (2015).
Obayashi, K. et al. Association of serum asymmetric dimethylarginine with muscle strength and gait speed: a cross-sectional study of the HEIJO-KYO cohort. J. Bone Miner. Res. 31, 1107–1113 (2016).
Luce, M. et al. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a clinically relevant uremic toxin in haemodialysis patients? Toxins 10, E205 (2018).
Gordon-Dseagu, V. L. Z. et al. The association of sleep with metabolic pathways and metabolites: evidence from the Dietary Approaches to Stop Hypertension (DASH)-sodium feeding study. Metabolomics 15, 48 (2019).
Leifheit-Nestler, M. & Haffner, D. Paracrine effects of FGF23 on the heart. Front. Endocrinol. 9, 278 (2018).
Huang, M. et al. The uremic toxin hippurate promotes endothelial dysfunction via the activation of Drp1-mediated mitochondrial fission. Redox Biol. 16, 303–313 (2018).
Ferrari, C. C. et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 24, 183–193 (2006).
Matsumoto, J. et al. TNF-α-sensitive brain pericytes activate microglia by releasing IL-6 through cooperation between IκB-NFκB and JAK-STAT3 pathways. Brain Res. 1692, 34–44 (2018).
Pu, T. et al. Persistent malfunction of glymphatic and meningeal lymphatic drainage in a mouse model of subarachnoid hemorrhage. Exp. Neurobiol. 28, 104–118 (2019).
Furukawa, S., Usuda, K., Abe, M., Hayashi, S. & Ogawa, I. Indole-3-acetic acid induces microencephaly in mouse fetuses. Exp. Toxicol. Pathol. 59, 43–52 (2007).
Adesso, S. et al. Indoxyl sulfate affects glial function increasing oxidative stress and neuroinflammation in chronic kidney disease: interaction between astrocytes and microglia. Front. Pharmacol. 8, 370 (2017).
Yeh, Y.-C. et al. Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease. Neurotoxicology 53, 148–152 (2016).
Fujita, Y. & Yamashita, T. The effects of leptin on glial cells in neurological diseases. Front. Neurosci. 13, 828 (2019).
Segura, S. et al. Leptin-dependent neurotoxicity via induction of apoptosis in adult rat neurogenic cells. Front. Cell. Neurosci. 9, 350 (2015).
Chun, H. J., Lee, Y., Kim, A. H. & Lee, J. Methylglyoxal causes cell death in neural progenitor cells and impairs adult hippocampal neurogenesis. Neurotox. Res. 29, 419–431 (2016).
Haddad, M. et al. Methylglyoxal and glyoxal as potential peripheral markers for MCI diagnosis and their effects on the expression of neurotrophic, inflammatory and neurodegenerative factors in neurons and in neuronal derived-extracellular vesicles. Int. J. Mol. Sci. 20, E4906 (2019).
Bird, M.-L., El Haber, N., Batchelor, F., Hill, K. & Wark, J. D. Vitamin D and parathyroid hormone are associated with gait instability and poor balance performance in mid-age to older aged women. Gait Posture 59, 71–75 (2018).
Rizwan Siddiqui, M. et al. Erythropoietin-mediated activation of aquaporin-4 channel for the treatment of experimental hydrocephalus. Childs Nerv. Syst. 34, 2195–2202 (2018).
Liu, D. et al. Hydrogen sulfide promotes proliferation and neuronal differentiation of neural stem cells and protects hypoxia-induced decrease in hippocampal neurogenesis. Pharmacol. Biochem. Behav. 116, 55–63 (2014).
Nath, N., Prasad, H. K. & Kumar, M. Cerebroprotective effects of hydrogen sulfide in homocysteine-induced neurovascular permeability: involvement of oxidative stress, arginase, and matrix metalloproteinase-9. J. Cell. Physiol. 234, 3007–3019 (2019).
Huang, T.-T., Hao, D.-L., Wu, B.-N., Mao, L.-L. & Zhang, J. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem. Biophys. Res. Commun. 493, 1443–1449 (2017).
Yang, N., Xu, L., Lin, P. & Cui, J. Uric acid promotes neuronal differentiation of human placenta-derived mesenchymal stem cells in a time- and concentration-dependent manner. Neural Regen. Res. 7, 756–760 (2012).
Yang, S., Zhang, X., Yuan, J., Yin, J. & Hu, W. Serum uric acid is independently associated with enlarged perivascular spaces. Sci. Rep. 7, 16435 (2017).
Moretti, R., Morelli, M. E. & Caruso, P. Vitamin D in neurological diseases: a rationale for a pathogenic impact. Int. J. Mol. Sci. 19, E2245 (2018).
Morello, M. et al. Vitamin D improves neurogenesis and cognition in a mouse model of Alzheimer’s disease. Mol. Neurobiol. 55, 6463–6479 (2018).
Beauchet, O. et al. Effects of Vitamin D and calcium fortified yogurts on gait, cognitive performances, and serum 25-hydroxyvitamin D concentrations in older community-dwelling females: results from the GAit, MEmory, Dietary and Vitamin D (GAME-D2) randomized controlled trial. Nutrients 11, E2880 (2019).
Hooper, S. R. et al. Neurocognitive, social-behavioral, and adaptive functioning in preschool children with mild to moderate kidney disease. J. Dev. Behav. Pediatr. 37, 231–238 (2016).
Hooper, S. R. et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 1824–1830 (2011).
Kendrick, J. et al. Acute kidney injury is associated with an increased risk of dementia. Kidney Int. Rep. 4, 1491–1493 (2019).
Alcocer-Castillejos, N., Jiménez-González, A. & Hinojosa-Azaola, A. No difference in cognitive dysfunction among patients with ANCA-associated vasculitis, rheumatoid arthritis or chronic kidney disease. J. Int. Neuropsychol. Soc. 25, 595–602 (2019).
Petersen, R. C. et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90, 126–135 (2018).
Weng, S.-C. et al. Progression of cognitive dysfunction in elderly chronic kidney disease patients in a veteran’s institution in central Taiwan: a 3-year longitudinal study. Intern. Med. 51, 29–35 (2012).
Murray, A. M. et al. Cognitive impairment in hemodialysis patients is common. Neurology 67, 216–223 (2006).
Kurella, M., Mapes, D. L., Port, F. K. & Chertow, G. M. Correlates and outcomes of dementia among dialysis patients: the dialysis outcomes and practice patterns study. Nephrol. Dial. Transpl. 21, 2543–2548 (2006).
Petersen, R. C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308 (1999).
The authors’ work was supported by the Swiss National Science Foundation (C.A.W.) and VALERE Programme by the University of Campania Luigi Vanvitelli (G.C.).
The authors declare no competing interests.
Peer review information
Nature Reviews Nephrology thanks S. Ferreira, N. Vaziri and D. Wolfgram for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Allen Brain Atlas database: https://human.brain-map.org/
ARCHS4 database: https://amp.pharm.mssm.edu/archs4/index.html
Human Protein Atlas database: https://www.proteinatlas.org/
WikiPathways database: https://www.wikipathways.org/index.php/WikiPathways
About this article
Cite this article
Viggiano, D., Wagner, C.A., Martino, G. et al. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol 16, 452–469 (2020). https://doi.org/10.1038/s41581-020-0266-9
Prevalence of mild cognitive impairment and its association with handgrip strength in patients on hemodialysis
Scientific Reports (2022)
Regional cerebral gray matter atrophy is associated with cognitive impairment in hemodialysis patients: a cross-sectional and longitudinal voxel-based morphological MRI study
Brain Imaging and Behavior (2022)
Prevalence of cognitive dysfunction and its risk factors in children with chronic kidney disease in a developing country
Pediatric Nephrology (2022)
Association of lipid accumulation product with chronic kidney disease in Chinese community adults: a report from the REACTION study
Lipids in Health and Disease (2021)
Renal Replacement Therapy (2021)